TY - JOUR
T1 - Spontaneous and Induced Animal Models for Cancer Research
AU - Onaciu, Anca
AU - Munteanu, Raluca
AU - Munteanu, Vlad Cristian
AU - Gulei, Diana
AU - Raduly, Lajos
AU - Feder, Richard Ionut
AU - Pirlog, Radu
AU - Atanasov, Atanas G.
AU - Korban, Schuyler S.
AU - Irimie, Alexandru
AU - Berindan-Neagoe, Ioana
N1 - Funding Information:
This research was funded by research grants from the Romanian Government: Project PNCDI III 2015?2020 entitled ?Increasing the performance of scientific research and technology transfer in translational medicine through the formation of a new generation of young researchers??ECHITAS, No. 29PFE/18.10.2018; Competitivity Operational Program, 2014?2020, entitled ?Clinical and economical impact of personalized targeted anti-microRNA therapies in reconverting lung cancer chemoresistance??CANTEMIR, No. 35/01.09.2016, MySMIS 103375; Project PN-III-P1-1.2-PCCDI2017-0737, grant 35/2018 entitled ?Genomic population mapping of radioactive and heavy metals in order to increase national security??ARTEMIS; Research grant ?Role and evaluation of new therapeutic targets in prostatic adenocarcinoma??PCD 2461/48, founded by Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania, and Research grant ?MicroRNAs in prostate adenocarcinoma. Diagnostic, prognostic and therapeutic role??PCD1530/43 founded by Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania and also published under the frame of European Social Found, Human Capital Operational Programme 2014-2020, project no. POCU/380/6/13/125171. The APC was funded by Project PNCDI III 2015?2020 entitled ?Increasing the performance of scientific research and technology transfer in translational medicine through the formation of a new generation of young researchers??ECHITAS.
Funding Information:
Funding: This research was funded by research grants from the Romanian Government: Project PNCDI III 2015–2020 entitled “Increasing the performance of scientific research and technology transfer in translational medicine through the formation of a new generation of young researchers”—ECHITAS, No. 29PFE/18.10.2018; Competitivity Operational Program, 2014–2020, entitled “Clinical and economical impact of personalized targeted anti-microRNA therapies in reconverting lung cancer chemoresistance”—CANTEMIR, No. 35/01.09.2016, MySMIS 103375; Project PN-III-P1-1.2-PCCDI2017-0737, grant 35/2018 entitled “Genomic population mapping of radioactive and heavy metals in order to increase national security”—ARTEMIS; Research grant “Role and evaluation of new therapeutic targets in prostatic adenocarcinoma”—PCD 2461/48, founded by Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania, and Research grant “MicroRNAs in prostate adenocarcinoma. Diagnostic, prognostic and therapeutic role”—PCD1530/43 founded by Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania and also published under the frame of European Social Found, Human Capital Operational Programme 2014-2020, project no. POCU/380/6/13/125171. The APC was funded by Project PNCDI III 2015–2020 entitled “Increasing the performance of scientific research and technology transfer in translational medicine through the formation of a new generation of young researchers”—ECHITAS.
PY - 2020/8/31
Y1 - 2020/8/31
N2 - Considering the complexity of the current framework in oncology, the relevance of animal models in biomedical research is critical in light of the capacity to produce valuable data with clinical translation. The laboratory mouse is the most common animal model used in cancer research due to its high adaptation to different environments, genetic variability, and physiological similarities with humans. Beginning with spontaneous mutations arising in mice colonies that allow for pursuing studies of specific pathological conditions, this area of in vivo research has significantly evolved, now capable of generating humanized mice models encompassing the human immune system in biological correlation with human tumor xenografts. Moreover, the era of genetic engineering, especially of the hijacking CRISPR/Cas9 technique, offers powerful tools in designing and developing various mouse strains. Within this article, we will cover the principal mouse models used in oncology research, beginning with behavioral science of animals vs. humans, and continuing on with genetically engineered mice, microsurgical-induced cancer models, and avatar mouse models for personalized cancer therapy. Moreover, the area of spontaneous large animal models for cancer research will be briefly presented.
AB - Considering the complexity of the current framework in oncology, the relevance of animal models in biomedical research is critical in light of the capacity to produce valuable data with clinical translation. The laboratory mouse is the most common animal model used in cancer research due to its high adaptation to different environments, genetic variability, and physiological similarities with humans. Beginning with spontaneous mutations arising in mice colonies that allow for pursuing studies of specific pathological conditions, this area of in vivo research has significantly evolved, now capable of generating humanized mice models encompassing the human immune system in biological correlation with human tumor xenografts. Moreover, the era of genetic engineering, especially of the hijacking CRISPR/Cas9 technique, offers powerful tools in designing and developing various mouse strains. Within this article, we will cover the principal mouse models used in oncology research, beginning with behavioral science of animals vs. humans, and continuing on with genetically engineered mice, microsurgical-induced cancer models, and avatar mouse models for personalized cancer therapy. Moreover, the area of spontaneous large animal models for cancer research will be briefly presented.
KW - Avatar mice
KW - Biomedical research
KW - Cancer
KW - Genetically modified
KW - Models of disease
KW - Preclinical studies
KW - Therapy
UR - http://www.scopus.com/inward/record.url?scp=85090742307&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090742307&partnerID=8YFLogxK
U2 - 10.3390/diagnostics10090660
DO - 10.3390/diagnostics10090660
M3 - Review article
C2 - 32878340
SN - 2075-4418
VL - 10
JO - Diagnostics
JF - Diagnostics
IS - 9
M1 - 660
ER -